Business Irish

Sunday 25 February 2018

Elan rejects 'low valuation' from Royalty

John Mulligan

John Mulligan

DRUG company Elan has dismissed low valuations placed on its assets by US-based Royalty Pharma, which has targeted the firm in a $6.4bn (€5bn) hostile takeover bid.

Elan said Royalty's bid "substantially undervalues it".

The Irish company claimed in a letter to shareholders yesterday that its shares are worth between $15.50 and $20.80 each. That is much higher than the $12.50 Royalty insists they are worth.

Elan sold its 50pc stake in multiple sclerosis drug Tysabri for $3.25bn earlier this year, but will continue to receive substantial royalties from sales of the treatment.

The firm has unveiled a number of transactions from share buybacks to company acquisitions as it seeks to reinvent itself following the Tysabri disposal.

Irish Independent

Promoted Links

Business Newsletter

Read the leading stories from the world of Business.

Promoted Links

Also in Business